S&P ASX All Technology

US Dollar vs AUD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

CANF Can Fite BioPharma Ltd

2.16

0.11 (5.37%)

28 Nov 2024 - Closed

Delayed by 15 minutes

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

null

Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Oct 2024 to Nov 2024

Click Here for more Can Fite BioPharma Charts.

Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Nov 2023 to Nov 2024

Click Here for more Can Fite BioPharma Charts.

Can Fite BioPharma Ltd News

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Friday 15 November 2024 (2 weeks ago) • Edgar (US Regulatory)

Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial
Monday 11 November 2024 (2 weeks ago) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Monday 4 November 2024 (3 weeks ago) • Edgar (US Regulatory)

Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia
Monday 4 November 2024 (3 weeks ago) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Saturday 19 October 2024 (1 month ago) • Edgar (US Regulatory)

Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson
Saturday 19 October 2024 (1 month ago) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Wednesday 9 October 2024 (2 months ago) • Edgar (US Regulatory)

FDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson for Pancreatic Cancer
Wednesday 9 October 2024 (2 months ago) • GlobeNewswire Inc.

Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on October 29
Monday 7 October 2024 (2 months ago) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Tuesday 24 September 2024 (2 months ago) • Edgar (US Regulatory)

Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary Osteoarthritis
Tuesday 24 September 2024 (2 months ago) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Monday 16 September 2024 (2 months ago) • Edgar (US Regulatory)

More Can Fite BioPharma Ltd News Articles

Verizon Communications

Woodside Petroleum

S&P ASX 300 Metals and M...

National Australia Bank

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions